Abstract
Pharmaceutical clinical research departments frequently prepare developmental programs for new agents. For any given indication, these plans invariably differ among companies due to unique perspectives and practices within the company; however, most often, the plans follow guidelines for drug development that are issued by the Food and Drug Administration.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers
About this chapter
Cite this chapter
Marder, H.K., Littman, G. (1990). The Cost and Time to Develop a New Antihypertensive Drug Depending upon the Endpoint. In: Morganroth, J., Moore, E.N. (eds) Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia. Developments in Cardiovascular Medicine, vol 112. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1505-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1505-6_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8809-1
Online ISBN: 978-1-4613-1505-6
eBook Packages: Springer Book Archive